Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial.
Monica N KhattakAnna M ChichuraJulie E LangPublished in: Annals of surgical oncology (2023)
This ASO perspective reviews the findings of a randomized, phase II clinical trial evaluating adjuvant trastuzumab emtansine (T-DM1) compared with paclitaxel and trastuzumab (TH) in stage I human epidermal growth factor receptor 2-positive breast cancer, as reported recently by the ATEMPT trial investigators. Patients treated with T-DM1 had better disease-free survival but did not have fewer treatment toxicities. The T-DM1-treated group had higher rates of treatment discontinuations, therefore long-term follow-up will be required to evaluate survival differences between T-DM1 and TH.
Keyphrases
- positive breast cancer
- epidermal growth factor receptor
- phase ii
- clinical trial
- tyrosine kinase
- metastatic breast cancer
- free survival
- open label
- advanced non small cell lung cancer
- phase iii
- study protocol
- early stage
- endothelial cells
- double blind
- randomized controlled trial
- systematic review
- placebo controlled
- metabolic syndrome
- skeletal muscle
- weight loss